No profile data available.
SOPHiA Genetics SA (SOPH) is a healthcare company in the medical sector application systems industry, based in Rolle, Switzerland, with about 415 full-time employees.
It reported revenue of $65.17 million for fiscal year 2024, up 4.5% from fiscal year 2023, and net income of -$62.49 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $19.46 million, up 22.8% from a year before. Rest of Europe, The Middle East, and Africa was its largest region in fiscal year 2025, with 33% of revenue. Its market capitalization was $630.80 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. It offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities.
SOPHiA Genetics SA reported $65.17 million in revenue for fiscal year 2024, up 4.5% from $62.37 million in fiscal year 2023. In Q3 2025 revenue was $19.46 million.
Rest of Europe, The Middle East, and Africa: 33% of revenue by region in fiscal year 2025, followed by France (15%).
$630.80 million as of October 9, 2026.
Listed companies of a similar size in the same industry (medical sector application systems) include Certara, Inc. (CERT), HealthStream, Inc. (HSTM), Phreesia, Inc. (PHR), Claritev Corp (CTEV).